ArticleFrontiers in immunology2017
CD161
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 40 citations in OpenAlex.
- Efforts towards a precision medicine approach in juvenile idiopathic arthritis.Rheumatology (Oxford, England) · 2026Review
- Identification of distinct subgroups in Chinese patients with Behçet's syndrome via cluster analysis of immune cells and clinical features.Arthritis research & therapy · 2026Article
- CD161⁺ Treg as a potential biomarker for evaluating disease activity and treatment efficacy in rheumatoid arthritis.Clinical rheumatology · 2026Article
- Identification and validation of KLRB1-related biomarkers in rheumatoid arthritis.Scientific reports · 2026Article
- The gut-joint axis in juvenile idiopathic arthritis.Arthritis research & therapy · 2026Review
- Elevated Peripheral CD161ACR open rheumatology · 2026Article
- Systems analysis unravels a common rural-urban gradient in immunological profile, function, and metabolic dependencies.Science advances · 2025Article
- Anti-SSA/SSB antibody double-negative Sjögren's disease patients: a comprehensive clinical study and immune profile.Clinical rheumatology · 2025Observational
- The 'TNature reviews. Rheumatology · 2025Review
- Treg cell plasticity as a driver of inflammation in spondyloarthritis and psoriasis.Frontiers in immunology · 2025Review
- Regulatory T Cell Dysfunction in Autoimmune Diseases.International journal of molecular sciences · 2024Review
- Distinct cellular immune responses in children en route to type 1 diabetes with different first-appearing autoantibodies.Nature communications · 2024Article
- The clinical and experimental treatment of Juvenile Idiopathic Arthritis.Clinical and experimental immunology · 2023Review
- Psoriatic and rheumatoid arthritis joints differ in the composition of CD8+ tissue-resident memory T cell subsets.Cell reports · 2023Article
- Immune phenotype changes in IgG4-related disease: CD161 + Treg and Foxp3 + Treg.Clinical rheumatology · 2023Article
- Article
- Retinoic acid signaling acts as a rheostat to balance Treg function.Cellular & molecular immunology · 2022Article
- CD1d-independent NK1.1Frontiers in immunology · 2022Article
- CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors.Journal for immunotherapy of cancer · 2022Article
- Single cell analysis of spondyloarthritis regulatory T cells identifies distinct synovial gene expression patterns and clonal fates.Communications biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human regulatory T cells (Treg) are important in immune regulation, but can also show plasticity in specific settings. CD161 is a lectin-like receptor and its expression identifies an effector-like Treg population. Here, we determined how CD161
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.